BYSI ▼ -2.7% - BeyondSpring Inc.
$BYSI - BeyondSpring Announces FDA Fast Track Designation for Plinabulin in Post-ICI Non-Squamous NSCLC and Strategic Transaction to Advance Global Phase 3 DUBLIN-4 Trial Toward Planned Interim Analysis
29-SEP-2026 07:01 AM ET
Share this post
💬 Comments
Loading comments…
Leave a comment
